Cargando…
Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
BACKGROUND: SARS-CoV-2 breakthrough infections after complete vaccination are increasing whereas their determinants remain uncharacterized. METHODS: We analyzed two cases of post-vaccination SARS-CoV-2 infections by α and β variants, respectively. For each participant both humoral (binding and neutr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905643/ https://www.ncbi.nlm.nih.gov/pubmed/35281046 http://dx.doi.org/10.3389/fimmu.2022.790212 |
_version_ | 1784665233978032128 |
---|---|
author | Gallais, Floriane Gantner, Pierre Planas, Delphine Solis, Morgane Bruel, Timothée Pierre, Florian Soulier, Eric Rossolillo, Paola Fourati, Slim Sibilia, Jean Schwartz, Olivier Fafi-Kremer, Samira |
author_facet | Gallais, Floriane Gantner, Pierre Planas, Delphine Solis, Morgane Bruel, Timothée Pierre, Florian Soulier, Eric Rossolillo, Paola Fourati, Slim Sibilia, Jean Schwartz, Olivier Fafi-Kremer, Samira |
author_sort | Gallais, Floriane |
collection | PubMed |
description | BACKGROUND: SARS-CoV-2 breakthrough infections after complete vaccination are increasing whereas their determinants remain uncharacterized. METHODS: We analyzed two cases of post-vaccination SARS-CoV-2 infections by α and β variants, respectively. For each participant both humoral (binding and neutralizing antibodies) and cellular (activation markers and cytokine expression) immune responses were characterized longitudinally. RESULTS: The first participant (P1) was infected by an α variant and displayed an extended and short period of viral excretion and symptom. Analysis of cellular and humoral response 72 h post-symptom onset revealed that P1 failed at developing neutralizing antibodies and a potent CD4 memory response (lack of SARS-CoV-2 specific CD4(+)IL-2(+) cells) and CD8 effector response (CD8(+)IFNγ(+) cells). The second participant (P2) developed post-vaccination SARS-CoV-2 infection by a β variant, associated with a short period of viral excretion and symptoms. Despite displaying initially high levels and polyfunctional T cell responses, P2 lacked initial β-directed neutralizing antibodies. Both participants developed and/or increased their neutralization activity and cellular responses against all variants, namely, β and δ variants that lasts up to 3 months after breakthrough infection. CONCLUSIONS: An analysis of cellular and humoral response suggests two possible mechanisms of breakthrough infection: a poor immune response to vaccine and viral evasion to neutralizing antibodies. |
format | Online Article Text |
id | pubmed-8905643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89056432022-03-10 Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine Gallais, Floriane Gantner, Pierre Planas, Delphine Solis, Morgane Bruel, Timothée Pierre, Florian Soulier, Eric Rossolillo, Paola Fourati, Slim Sibilia, Jean Schwartz, Olivier Fafi-Kremer, Samira Front Immunol Immunology BACKGROUND: SARS-CoV-2 breakthrough infections after complete vaccination are increasing whereas their determinants remain uncharacterized. METHODS: We analyzed two cases of post-vaccination SARS-CoV-2 infections by α and β variants, respectively. For each participant both humoral (binding and neutralizing antibodies) and cellular (activation markers and cytokine expression) immune responses were characterized longitudinally. RESULTS: The first participant (P1) was infected by an α variant and displayed an extended and short period of viral excretion and symptom. Analysis of cellular and humoral response 72 h post-symptom onset revealed that P1 failed at developing neutralizing antibodies and a potent CD4 memory response (lack of SARS-CoV-2 specific CD4(+)IL-2(+) cells) and CD8 effector response (CD8(+)IFNγ(+) cells). The second participant (P2) developed post-vaccination SARS-CoV-2 infection by a β variant, associated with a short period of viral excretion and symptoms. Despite displaying initially high levels and polyfunctional T cell responses, P2 lacked initial β-directed neutralizing antibodies. Both participants developed and/or increased their neutralization activity and cellular responses against all variants, namely, β and δ variants that lasts up to 3 months after breakthrough infection. CONCLUSIONS: An analysis of cellular and humoral response suggests two possible mechanisms of breakthrough infection: a poor immune response to vaccine and viral evasion to neutralizing antibodies. Frontiers Media S.A. 2022-02-23 /pmc/articles/PMC8905643/ /pubmed/35281046 http://dx.doi.org/10.3389/fimmu.2022.790212 Text en Copyright © 2022 Gallais, Gantner, Planas, Solis, Bruel, Pierre, Soulier, Rossolillo, Fourati, Sibilia, Schwartz and Fafi-Kremer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Gallais, Floriane Gantner, Pierre Planas, Delphine Solis, Morgane Bruel, Timothée Pierre, Florian Soulier, Eric Rossolillo, Paola Fourati, Slim Sibilia, Jean Schwartz, Olivier Fafi-Kremer, Samira Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine |
title | Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine |
title_full | Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine |
title_fullStr | Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine |
title_full_unstemmed | Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine |
title_short | Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine |
title_sort | case report: evolution of humoral and cellular immunity in two covid-19 breakthrough infections after bnt162b2 vaccine |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905643/ https://www.ncbi.nlm.nih.gov/pubmed/35281046 http://dx.doi.org/10.3389/fimmu.2022.790212 |
work_keys_str_mv | AT gallaisfloriane casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT gantnerpierre casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT planasdelphine casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT solismorgane casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT brueltimothee casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT pierreflorian casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT souliereric casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT rossolillopaola casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT fouratislim casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT sibiliajean casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT schwartzolivier casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine AT fafikremersamira casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine |